Biogen Inc.

BIIB

Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.

Revenue
+10.6%
EPS
−104.4%
Free cash flow
−69.3%
Total debt
+16.0%

Quarter to September 2026, against a year earlier

248.35 4.42 +1.81%
Market cap
$36.1B
P/E
105×
Fwd P/E
46.4×
Dividend yield
—
F-score
4/9
ROIC
1.94%
Net debt / EBITDA
0.8×
Dividend safety
n/a

Biogen Inc. (BIIB) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Biogen Inc. (BIIB) trades at a P/E ratio of 105×. Over the past ten years it has ranged from 7.7× (July 2020) to 108× (November 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 26.5× and above the Healthcare sector median of 24.5×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 19.9× 46.24%
FY2024 13.6× (59.12%)
FY2023 33.3× 156.68%
FY2022 13.0× (43.53%)
FY2021 23.0× 130.16%
FY2020 10.0× 6.16%
FY2019 9.4× (32.30%)
FY2018 13.9× (50.36%)
FY2017 28.0× 73.82%
FY2016 16.1× (19.15%)

Quarterly newest first

Period P/E ratio Change
Sep 2026 95.7× 151.55%
Jun 2026 38.0× 94.00%
Mar 2026 19.6× (1.62%)
Dec 2025 19.9× 56.37%
43 more quarters

Against its own ten years

Low 7.7× High 108×
Ten-year median 17.1×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
GILD Gilead Sciences, Inc. compare n/m
NVO Novo Nordisk A/S compare 10.1×
BMY Bristol Myers Squibb Company compare 13.7×
GSK GSK PLC Sponsored ADR compare 16.7×
SNY Sanofi compare 23.3×
AZN AstraZeneca PLC compare 26.2×
AMGN Amgen Inc. compare 26.5×
PFE Pfizer Inc. compare 41.3×
BIIB Biogen Inc. 105×
Drug Manufacturers General industry median 26.5×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BIIB